Utama › Limfoma Sel B Besar Difus
Kajian klinikal Limfoma Sel B Besar Difus sedang mengambil peserta di AS
101 kajian untuk Limfoma Sel B Besar Difus sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- New York City, NY21 kajian
- Baldwin Park, CA19 kajian
- Chicago, IL18 kajian
- Houston, TX17 kajian
- Los Angeles, CA17 kajian
- Boston, MA16 kajian
- Milwaukee, WI16 kajian
- Nashville, TN15 kajian
- Portland, OR15 kajian
- Philadelphia, PA15 kajian
- Durham, NC14 kajian
- Dallas, TX13 kajian
- Seattle, WA12 kajian
- Salt Lake City, UT12 kajian
- Washington, DC12 kajian
- Denver, CO11 kajian
- Cincinnati, OH11 kajian
- Cleveland, OH11 kajian
- Rochester, MN10 kajian
- Atlanta, GA10 kajian
- Richmond, VA10 kajian
- Columbus, OH9 kajian
- Edison, NJ9 kajian
- Omaha, NE9 kajian
- Cedar Rapids, IA9 kajian
- San Antonio, TX8 kajian
- Sacramento, CA8 kajian
- Greenburgh, NY8 kajian
- Jacksonville, FL8 kajian
- Louisville, KY8 kajian
- St. Louis, MO8 kajian
- San Francisco, CA8 kajian
- New Haven, CT8 kajian
- Grand Rapids, MI8 kajian
- Indianapolis, IN7 kajian
- Charlottesville, VA7 kajian
- Miami, FL7 kajian
- Kansas City, MO7 kajian
- Aurora, CO7 kajian
- Pittsburgh, PA6 kajian
Mengikut negeri
- Alabama4 kajian
- Arizona13 kajian
- Arkansas4 kajian
- California42 kajian
- Colorado19 kajian
- Connecticut8 kajian
- Florida23 kajian
- Georgia15 kajian
- Idaho4 kajian
- Illinois22 kajian
- Indiana9 kajian
- Iowa11 kajian
- Kansas7 kajian
- Kentucky11 kajian
- Louisiana6 kajian
- Maryland13 kajian
- Massachusetts16 kajian
- Michigan15 kajian
- Minnesota16 kajian
- Missouri8 kajian
- Montana4 kajian
- Nebraska9 kajian
- Nevada3 kajian
- New Jersey13 kajian
- New Mexico3 kajian
- New York31 kajian
- North Carolina20 kajian
- North Dakota4 kajian
- Ohio23 kajian
- Oklahoma5 kajian
- Oregon15 kajian
- Pennsylvania19 kajian
- South Carolina4 kajian
- South Dakota3 kajian
- Tennessee19 kajian
- Texas29 kajian
- Utah14 kajian
- Virginia17 kajian
- Washington17 kajian
- Wilayah Columbia4 kajian
- Wisconsin19 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06863402Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06834373Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07763210Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06649812Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Mengambil pesertaFasa 2
Umur 65 hingga 99 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06091865A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06890884Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT05272384Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.